Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379469 | 0.91 | ESR1 (0.49) | ESR1KDRAURKBFGFR1BRAF | |
| SCHEMBL379662 | 0.91 | CCNC (0.49) | ESR1KDRAURKBFGFR1BRAF | |
| SCHEMBL379874 | 0.90 | CCNC (0.47) | ESR1KDRAURKBFGFR1BRAF | |
| SCHEMBL379947 | 0.89 | KDR (0.45) | ESR1KDRAURKBFGFR1BRAF | |
| SCHEMBL379184 | 0.88 | KDR (0.49) | KDRAURKBFGFR1BRAFCCNC | |
| SCHEMBL379554 | 0.86 | BRAF (0.52) | ESR1KDRAURKBBRAFCCNC | |
| SCHEMBL379876 | 0.86 | BTK (0.47) | ESR1KDRAURKBBRAFTP53 | |
| SCHEMBL379873 | 0.85 | PIP4K2C (0.56) | KDRAURKBFGFR1BRAFCYP3A4 | |
| SCHEMBL379872 | 0.85 | CCNC (0.42) | ESR1KDRAURKBFGFR1BRAF | |
| SCHEMBL379543 | 0.85 | THRB (0.44) | ESR1KDRAURKBFGFR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216992-B2 | Thieno[3,2-c]pyridine potassium channel inhibitors | XENTION LIMITED (GB) | 2015-12-22 | — | — | US | claimed |
| EP-1968982-B1 | THIENO (3,2-C) PYRIDINE COMPOUNDS | XENTION LTD (GB) | 2012-01-25 | — | — | EP | claimed |
| EP-1968982-A2 | THIENO (3,2-C) PYRIDINE COMPOUNDS | Xention Discovery Ltd. (GB) | 2008-09-17 | — | — | EP | claimed |
| US-20070161672-A1 | Compounds | XENTION LIMITED | 2007-07-12 | — | — | US | claimed |
| WO-2007066127-A2 | THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS | XENTION LIMITED (GB) | 2007-06-14 | — | — | WO | claimed |
| US-9216992-B2 | Thieno[3,2-c]pyridine potassium channel inhibitors | XENTION LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| EP-1968982-B1 | THIENO (3,2-C) PYRIDINE COMPOUNDS | XENTION LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1968982-A2 | THIENO (3,2-C) PYRIDINE COMPOUNDS | Xention Discovery Ltd. (GB) | 2008-09-17 | — | — | EP | disclosed |
| US-20070161672-A1 | Compounds | XENTION LIMITED | 2007-07-12 | — | — | US | disclosed |
| WO-2007066127-A2 | THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS | XENTION LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161672-A1 | Compounds | KCNJ2, KCNT1, KCNT2 | ESR1 4761/4885KDR 2522/4885AURKB 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.